A systematic review and meta-analysis comparing radiofrequency catheter ablation with medical therapy for ventricular tachycardia in patients with ischemic and non-ischemic cardiomyopathies

Anti-racist strategies for clinical and translational research: Design, implementation, and lessons learned from a new course

“…Ten were published by a student with a faculty appointment [ 34 – 43 ]. Overall, there were 3 case reports [ 34 , 44 , 45 ], one case series [ 46 ], 2 editorials [ 41 , 43 ], 2 letters [ 37 , 47 ], 2 review articles [ 48 , 49 ], 7 systematic reviews [ 35 , 36 , 38 – 40 , 42 , 50 ], 2 retrospective cohort studies [ 51 , 52 ], an evaluation of mobile health applications [ 53 ], and a medical education report. [ 54 ] One case report noted the subject’s race, without further comment [ 44 ].…”

“…Ten were published by a student with a faculty appointment [34][35][36][37][38][39][40][41][42][43]. Overall, there were 3 case reports [34,44,45], one case series [46], 2 editorials [41,43], 2 letters [37,47], 2 review articles [48,49], 7 systematic reviews [35,36,[38][39][40]42,50], 2 retrospective cohort studies [51,52], an evaluation of mobile health applications [53], and a medical education report. [54] One case report noted the subject's race, without further comment [44].…”

Cardioneuroablation for treatment of carotid sinus syndrome secondary to oropharyngeal squamous cell cancer

“…However, a consensus on the optimal mapping method, ablation foci, or procedural endpoints has not been reached yet. 10,16,17 Recent ESC guidelines have cited CNA as a potential method for the treatment of VVS, but did not provide any class of recommendations. 1 For this, well-designed, double-blind, multicenter, sham-controlled randomized clinical trials are needed.…”

Considerations on outcomes, patient selection, and safety of catheter ablation for ventricular arrhythmias

“…First, Ravi et al report an updated systematic review and study-level meta-analysis of 11 studies (9 randomized control trials (RCTs) and 2 observational studies) comparing CA to medical therapy with antiarrhythmic drugs (AADs), including 3 contemporary trials published in 2022 [7]. While the primary pooled RCT analysis of 1103 patients found no difference in all-cause mortality between groups (RR 0.94, p = 0.71), CA was associated with a significant decrease in ICD shocks (RR 0.64, p = 0.008), recurrent VT (RR 0.79, p = 0.005), and cardiac hospitalizations (RR 0.76, p = 0.005) compared to AAD therapy.…”